[go: up one dir, main page]

AR072936A1 - Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer. - Google Patents

Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer.

Info

Publication number
AR072936A1
AR072936A1 ARP090103156A ARP090103156A AR072936A1 AR 072936 A1 AR072936 A1 AR 072936A1 AR P090103156 A ARP090103156 A AR P090103156A AR P090103156 A ARP090103156 A AR P090103156A AR 072936 A1 AR072936 A1 AR 072936A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
cycloalkyl
heteroaryl
heterobicycloaryl
Prior art date
Application number
ARP090103156A
Other languages
English (en)
Inventor
John D Lawson
Lily Kwok
Michael B Wallace
Jeffrey A Stafford
Philip Erickson
Mallareddy Komandla
Jerome C Bressi
Shaosong Chu
Sanjib Das
Zhiyuan Zhang
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR072936A1 publication Critical patent/AR072936A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Reivindicacion 1: Un compuesto que tiene la formula (1) o una de sus sales farmacéuticamente aceptables, en donde G se selecciona del grupo que consiste en CR4 y N; J se selecciona del grupo que consiste en CR5 y N; K se selecciona del grupo que consiste en CR6 y N; M se selecciona del grupo que consiste en CR7 y N; L está ausente o un ligador que provee 1, 2, 3, 4, 5 o 6 separacion de átomos entre los anillos a los que L se une, en donde los átomos del ligador que provee la separacion se seleccionan del grupo que consiste en carbono, oxígeno, nitrogeno y azufre; T se selecciona del grupo que consiste en CR8 y N; U se seleccione del grupo que consiste en CR9 y N; V se selecciona del grupo que consiste en CR10 y N; W se selecciona del grupo que consiste en CR11 y N; X se selecciona del grupo que consiste en CR12 y N; Y se selecciona del grupo que consiste en CR13 y N; Z se selecciona del grupo que consiste en CR14R15 y NR16; R1 se selecciona del grupo que consiste en hidrogeno, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, alquilcarbonilo C1-10, cicloalquil C3-12carbonilo C1-5, heterocicloalquil C3-12carbonilo C1-10, arilcarbonilo C1-10, heteroaril C1-10carbonilo C1-5, bicicloaril C9-12carbonilo C1-5, heterobicicloaril C8-12carbonilo C1-5, amino, alquil C1-10 amino, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12alquilo C1-5, heterocicloalquil C3-12alquilo C1-10, arilalquilo C1-10, heteroaril C1-10alquilo C1-5, bicicloaril C9-12alquilo C1-5, heterobicicloaril C8-12alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C4-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R1 tiene la formula -C(=O)-R19; R2 es hidrogeno o un sustituyente convertible in vivo a hidrogeno; R3 se selecciona del grupo que consiste en hidrogeno, carboniloxi. alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquil C1-10amino, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12alquilo C1-5, heterocicloalquil C3-12alquilo C1-10, arilalquilo C1-10, heteroaril C1-10alquilo C1-5, bicicloaril C9-12alquilo C1-5, heterobicicloaril C8-12alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C4-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R3 está ausente cuando el nitrogeno al que está unido forma parte de un doble enlace; R4 se selecciona del grupo que consiste en hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquil C1-10amino, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12alquilo C1-5, heterocicloalquil C3-12alquilo C1-10, arilalquilo C1-10, heteroaril C1-10alquilo C1-5, bicicloaril C9-12alquilo C1-5, heterobicicloaril C8-12alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C4-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R5 se selecciona del grupo que consiste en hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquil C1-10amino, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12alquilo C1-5, heterocicloalquil C3-12alquilo C1-10, arilalquilo C1-10, heteroaril C1-10alquilo C1-5, bicicloaril C9-12alquilo C1-5, heterobicicloaril C8-12alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C4-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R6 se selecciona del grupo que consiste en hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquil C1-10amino, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12alquilo C1-5, heterocicloalquil C3-12alquilo C1-10, arilalquilo C1-10, heteroaril C1-10alquilo C1-5, bicicloaril C9-12alquilo C1-5, heterobicicloaril C8-12alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C4-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R7 se selecciona del grupo que consiste en hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquil C1-10amino, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12alquilo C1-5, heterocicloalquil C3-12alquilo C1-10, arilalquilo C1-10, heteroaril C1-10alquilo C1-5, bicicloaril C9-12alquilo C1-5, heterobicicloaril C8-12alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C4-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R8 se selecciona del grupo que consiste en hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquil C1-10amino, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12alquilo C1-5, heterocicloalquil C3-12alquilo C1-10, arilalquilo C1-10, heteroaril C1-10alquilo C1-5, bicicloaril C9-12alquilo C1-5, heterobicicloaril C8-12alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C4-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R9 se selecciona del grupo que consiste en hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquil C1-10amino, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12alquilo C1-5, heterocicloalquil C3-12alquilo C1-10, arilalquilo C1-10, heteroaril C1-10alquilo C1-5, bicicloaril C9-12alquilo C1-5, heterobicicloaril C8-12alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, carbonilarilo C4-12, heteroarilo C4-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R10 se selecciona del grupo que consiste en hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquil C1-10amino, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12alquilo C1-5, heterocicloalquil C3-12alquilo C1-10, arilalquilo C1-10, heteroaril C1-10alquilo C1-5, bicicloaril C9-12alquilo C1-5, heterobicicloaril C8-12alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, carbonilarilo C4-12, heteroarilo C4-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R11 se selecciona del grupo que consiste en hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquil C1-10amino, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquil C3
ARP090103156A 2008-08-14 2009-08-14 Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer. AR072936A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8895908P 2008-08-14 2008-08-14
US11791008P 2008-11-25 2008-11-25
US16100709P 2009-03-17 2009-03-17

Publications (1)

Publication Number Publication Date
AR072936A1 true AR072936A1 (es) 2010-09-29

Family

ID=41202532

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103156A AR072936A1 (es) 2008-08-14 2009-08-14 Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer.

Country Status (26)

Country Link
US (1) US8178534B2 (es)
EP (1) EP2313407B1 (es)
JP (1) JP5469666B2 (es)
KR (1) KR20110039383A (es)
CN (1) CN102124005B (es)
AR (1) AR072936A1 (es)
AU (1) AU2009281822B2 (es)
BR (1) BRPI0917808A2 (es)
CA (1) CA2731108A1 (es)
CO (1) CO6351724A2 (es)
CR (1) CR20110135A (es)
DO (1) DOP2011000050A (es)
EA (1) EA019723B1 (es)
EC (1) ECSP11010889A (es)
ES (1) ES2608761T3 (es)
GE (1) GEP20125652B (es)
IL (1) IL210734A0 (es)
MA (1) MA32615B1 (es)
MX (1) MX2011001732A (es)
MY (1) MY150542A (es)
NZ (1) NZ590617A (es)
PE (1) PE20110275A1 (es)
TW (1) TWI455939B (es)
UY (1) UY32049A (es)
WO (1) WO2010019899A1 (es)
ZA (1) ZA201100467B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US20090197880A1 (en) * 2007-07-13 2009-08-06 Genelabs Technologies, Inc. Anti-viral compounds, compositions, and methods of use
NZ584148A (en) 2007-09-14 2011-05-27 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
DK2200985T3 (da) 2007-09-14 2011-10-24 Ortho Mcneil Janssen Pharm 1,3-Disubstituerede 4-(aryl--X-phenyl)-1H-pyridin-2-oner
KR101520086B1 (ko) 2007-09-14 2015-05-14 얀센 파마슈티칼스 인코포레이티드 １´,３´-이치환된-４-페닐-３,４,５,６-테트라히드로-２ｈ,１´ｈ-[１,４´]비피리디닐-２´-온
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
EP2444403A1 (en) * 2008-04-18 2012-04-25 Shionogi Co., Ltd. Heterocyclic compound having inhibitory activity on PI3K
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CN102186477B (zh) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物
RU2512283C2 (ru) 2008-11-28 2014-04-10 Янссен Фармасьютикалз, Инк. Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2409006T3 (es) 2009-05-12 2013-06-24 Janssen Pharmaceuticals Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
DK3795573T3 (da) 2009-12-31 2022-09-19 Hutchison Medipharma Ltd Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
NZ703111A (en) * 2010-05-17 2016-07-29 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
US20130315895A1 (en) * 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
WO2013135674A1 (en) * 2012-03-12 2013-09-19 Syngenta Participations Ag Insecticidal 2-aryl-acetamide compounds
SMT202000673T1 (it) 2012-06-13 2021-01-05 Incyte Holdings Corp Composti triciclici sostituiti come inibitori di fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG11201508328PA (en) 2013-04-19 2015-11-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2014180182A1 (zh) * 2013-05-10 2014-11-13 江苏豪森药业股份有限公司 [1,2,4]三唑并[4,3-a]吡啶类衍生物，其制备方法或其在医药上的应用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
SG11201605742TA (en) 2014-01-21 2016-08-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
SG10201806846RA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PH12017501817B1 (en) 2015-04-03 2023-06-16 Incyte Holdings Corp Heterocyclic compounds as lsd1 inhibitors
ES2928684T3 (es) * 2015-06-25 2022-11-21 Taiho Pharmaceutical Co Ltd Agente terapéutico para la fibrosis
TWI765860B (zh) 2015-08-12 2022-06-01 美商英塞特公司 Lsd1抑制劑之鹽
CN108853108A (zh) * 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CN109071504B (zh) 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
BR112019010511A2 (pt) 2016-11-23 2019-09-17 Bayer Ag derivados de heterociclo bicíclico fundido como pesticidas
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
CA3053739C (en) 2017-02-15 2023-02-14 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
FI3788047T3 (fi) 2018-05-04 2024-11-02 Incyte Corp Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
AU2019395282A1 (en) 2018-12-14 2021-07-08 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
MX2024008648A (es) 2022-01-12 2024-09-23 Denali Therapeutics Inc Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719368D0 (en) 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
BRPI0620292B1 (pt) * 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
MX2009001349A (es) 2006-08-04 2009-04-17 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso.
EP2057164A1 (en) * 2006-08-07 2009-05-13 Incyte Corporation Triazolotriazines as kinase inhibitors
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
AU2007292924A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
WO2008051808A2 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
SI3034075T1 (sl) * 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
CN102015716B (zh) * 2008-02-28 2014-09-17 诺华股份有限公司 用于治疗C-Met酪氨酸激酶介导的疾病的咪唑并[1,2-b]哒嗪衍生物

Also Published As

Publication number Publication date
EP2313407B1 (en) 2016-10-05
AU2009281822B2 (en) 2014-11-13
BRPI0917808A2 (pt) 2019-09-24
EP2313407A1 (en) 2011-04-27
EA019723B1 (ru) 2014-05-30
ES2608761T3 (es) 2017-04-12
TWI455939B (zh) 2014-10-11
ECSP11010889A (es) 2011-04-29
PE20110275A1 (es) 2011-05-08
CA2731108A1 (en) 2010-02-18
AU2009281822A1 (en) 2010-02-18
CO6351724A2 (es) 2011-12-20
WO2010019899A1 (en) 2010-02-18
KR20110039383A (ko) 2011-04-15
JP5469666B2 (ja) 2014-04-16
NZ590617A (en) 2012-05-25
US20100063054A1 (en) 2010-03-11
ZA201100467B (en) 2012-03-28
GEP20125652B (en) 2012-09-25
TW201014857A (en) 2010-04-16
CR20110135A (es) 2011-09-27
EA201170295A1 (ru) 2011-08-30
IL210734A0 (en) 2011-03-31
MY150542A (en) 2014-01-30
CN102124005A (zh) 2011-07-13
JP2012500215A (ja) 2012-01-05
UY32049A (es) 2010-03-26
US8178534B2 (en) 2012-05-15
MX2011001732A (es) 2011-03-25
MA32615B1 (fr) 2011-09-01
DOP2011000050A (es) 2011-03-15
CN102124005B (zh) 2014-06-04

Similar Documents

Publication Publication Date Title
AR072936A1 (es) Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer.
AR071729A1 (es) Inhibidores de quinasas simil polo (plk)
AR054866A1 (es) Inhibidores de histona deacetilasa
AR048055A1 (es) Derivados de pirimidina como inhibidores de dipeptidil peptidasa
AR068140A1 (es) Amidas heterociclicas y metodos de uso de las mismas
AR071811A1 (es) Derivados de diazol como activadores de glucoquinasa
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
AR056194A1 (es) Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
AR059622A1 (es) Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles
AR063232A1 (es) Pirido (2,3) indoles como inhibidores de quinasas.composiciones farmaceuticas.
AR058124A1 (es) Derivados de ftalazinona como inhibidores de parp-1
AR052863A1 (es) Compuestos de quinolina heteroaromaticos
AR053436A1 (es) Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
AR068547A1 (es) Derivados de quinolina
AR071452A1 (es) Inhibidores de hsp90
AR106945A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR045455A1 (es) Derivados de pirimidina como inhibidores de dipeptidil peptidasa
CO6241101A2 (es) Derivados de quinolina como inhibidores de la p13 quinasa
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
MX2009002686A (es) Derivados de acetamida de quinazolinona e isoquinolinona.
AR056008A1 (es) Derivados de pirazina antagonistas del receptor a2b de adenosina
CY1113727T1 (el) Παραγωγα πυριδιν-4-υλ ως ανοσορυθμιστικοι παραγοντες
AR059218A1 (es) Derivados de pirimidina

Legal Events

Date Code Title Description
FB Suspension of granting procedure